Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Blue Sky Uranium Expands Drill Plan to Advance the Ivana Uranium-Vanadium Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Harrow Inc HROW

Healthcare Biotechnology
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America... see more

Recent & Breaking News (NDAQ:HROW)

Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity

PR Newswire August 28, 2013

Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT

PR Newswire August 5, 2013

Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Bleeding and Clotting Disorder Functional Antibiotic Drug Candidate

PR Newswire July 23, 2013

Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013

PR Newswire July 22, 2013

Faruqi & Faruqi, LLP Launches An Investigation Against Imprimis Pharmaceuticals, Inc. (IMMY) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Business Wire July 12, 2013

Imprimis Pharmaceuticals, Inc. set to join Russell Microcap Index

PR Newswire June 27, 2013

Imprimis Pharmaceuticals Begins Enacting Long-Term Business Strategy

Marketwired June 26, 2013

Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company

PR Newswire June 17, 2013

Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City

PR Newswire June 14, 2013

Imprimis Rising: Unique Pathway Requires Fewer and Smaller Clinical Trials

Marketwired May 8, 2013

Imprimis Pharmaceuticals, Inc. Concludes Type C Meeting at the FDA

PR Newswire April 18, 2013

Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option

PR Newswire March 13, 2013

Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products

PR Newswire March 4, 2013

Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock

PR Newswire February 7, 2013